New combination of old drugs improves survival

Disclosure:

G. Attard: Financial, personal interests, Guest speaker, null: Janssen; Financial, personal interests, advisory board, null: Janssen; Financial, personal interests, Guest speaker, null: Astellas; Financial, personal, advisory, null interests: Astellas; Financial, personal, advisory, null interests: Novartis; Financial, personal, advisory, null interests: Bayer; Financial, personal interests, Guest speaker, null: AstraZeneca; Financial, personal, advisory, null interests: AstraZeneca; Financial, personal, advisory, null interests: Pfizer; Financial, personal, advisory, null interests: Sanofi; Financial Interests, Personal, Advisory Council, null: Sapience; Financial, personal, advisory, nil interests: Orion; Financial, Personal Interests, Royalties, null: Janssen; Financial, institutional interests, research grant, null: Janssen; Financial, institutional, research grant, nil: Astellas; Non-financial interests,, principal investigator, null: Janssen; Non-financial interests,, Advisory role, null: Janssen; Non-financial interests,, Advisory role, null: AstraZeneca; Non-financial interests,, principal investigator, null: Astellas.
LC Brown: Financial Interests, Institutional, Research Grant, FOCUS4-C Trial from June 2017 to December 2021: AstraZeneca.
N. Clarke: Financial, personal interests, Guest speaker: Astellas; Financial, personal interests, Guest speaker: AstraZeneca; Financial, personal interests, Guest speaker: Ferring; Financial, personal interests, Guest speaker: Janssen; Financial, personal interests, advisory board: Astellas; Financial, personal interests, advisory board: AstraZeneca; Financial, personal, advisory board interests: Ferring; Financial, personal interests, advisory board: Janssen; Financial and institutional interests, research grant: AstraZeneca.
W. Cross: Financial interests, Staff, Guest speaker, Speaker fees: Myriad Genetics; Financial, personal, guest speaker, speaker fees: Janssen; Financial, personal, advisory board, advisory board fees: Bayer; Financial, personal interests, guest speaker, speaker fees: Astellas; Financial interests, Institutional, Research grant, Research grant: Myriad Genetics.
R. Jones: Financial, personal, advisory board, advisory board participation: AstraZeneca; Financial, personal interests, advisory board, participation in the advisory board: Astellas; Financial, personal interests, guest speaker, speaking fees: Astellas; Financial, personal, advisory, null interests: Bayer; Financial, personal interests, Guest speaker, null: Bayer; Financial, Personal, Advisory Board Interests, null: Clovis; Financial, Personal, Advisory Board Interests, null: Exelixis; Financial, Personal, Advisory Board Interests, null: Ipsen; Financial, personal interests, Guest speaker, null: Ipsen; Financial, personal, advisory, null interests: Bristol Myers Squipp; Financial, personal interests, Guest speaker, null: Bristol Myers Squibb; Financial, personal, advisory, null interests: Merck Serono; Financial, personal interests, Guest speaker, null: Merck Serono; Financial, personal, advisory, null interests: Merck Sharpe Dome; Financial, personal interests, Guest speaker, null: Merck Sharpe Dome; Financial, personal interests, Guest speaker, null: Pfizer; Financial interests, personal, advisory board, null: Roche; Financial, institutional, other interests, members of IDMC: Roche; Financial, personal interests, Guest speaker, null: Roche; Financial, personal interests, advisory board, null: Janssen; Financial, personal interests, Guest speaker, null: Janssen; Financial, institutional, other interests, member of IDMC: Stab; Financial, personal, advisory, null interests: Novartis / AAA; Financial, institutional interests, Guest speaker, null: Janssen; Financial, Institutional Interests, Guest Speaker, null: Pfizer; Financial, institutional interests, guest speaker, null: Tail; Financial, Institutional Interests, Guest Speaker, null: AstraZeneca; Financial, Institutional Interests, Guest Speaker, null: BioXcel; Financial, institutional interests, Guest speaker, null: Bristol Myers Squibb; Financial and Institutional Interests, Guest Speaker, null: Novartis / AAA; Financial, institutional interests, Guest speaker, null: Roche; Financial, institutional interests, guest speaker, null: MSK.
S. Gillessen: Financial Interests, Staff, Advisory Board, 2018: Sanofi; Financial, personal interests, advisory board, 2018, 2019: Orion; Financial interests, Staff, Advisory Board, 2018: Roche; Financial, personal interests, Guest speaker, 2019 Speakers bureau: Janssen Cilag; Financial, personal interests, advisory board, 2020: Amgen; Financial, personal interests, guest speaker, 2020: ESMO; Financial, personal, other interests, travel grant 2020: ProteoMEdiX; Financial, institutional interests, advisory board, 2018, 2019: Bayer; Financial, institutional interests, advisory board, 2020: Janssen Cilag; Financial, institutional interests, advisory board, 2020: Roche; Financial, institutional interests, advisory board, 2018: AAA International; Financial, institutional interests, advisory board, 2018: Menarini Silicon Biosystems; Financial, institutional interests, advisory board, 2019, 2020: Astellas Pharma; Financial, institutional interests, advisory board, 2019: Tolero Pharmaceuticals; Financial, institutional interests, advisory board, 2020: MSD Merck Sharp & Dohme; Financial, institutional interests, advisory board, 2020: Pfizer; Financial, personal interests, guest speaker, 2021: SAKK; Financial and Institutional Interests, Advisory Board, 2021: Telixpharma; Financial, Institutional and Other Interests, 2021 Steering Committee: Amgen; Financial and institutional interests, guest speaker, 2021: DESO; Financial, institutional interests, advisory board, 2021: BMS; Financial, institutional interests, advisory board, 2021: AAA International; Financial, institutional interests, advisory board, 2021: Orion; Financial, personal interests, guest speaker, 2021: SAKK; Financial, personal interests, guest speaker, 2021: SAKK; Financial, institutional interests, advisory board, 2021: Bayer; Financial, personal, advisory board interests, 2021: MSD Merck Sharp & Dhome; Financial, personal, other interests, 2021: RSI (Televisione Svizzera Italiana); Financial Interests, Personal, Guest Speaker, 2021: SAMO – IBCSG; Financial, institutional, funding, 2021, unrestricted grant for a study related to Covid as co-investigator: Astellas; Non-financial interests,, Advisory role, 2019: Menarini Silicon Biosystems; Non-financial interests,, Advisory role, 2019: Aranda; Non-financial interests,, Advisory role, Continuation: ProteoMediX.
S. Chowdhury: Financial, Personal, Advisory Board, Null: Astellas; Financial, personal interests, advisory board, null: Janssen; Financial, personal interests, Guest speaker, null: Janssen; Financial, personal, advisory, nil interests: Huma; Financial, personal interests, Guest speaker, null: AstraZeneca; Financial, personal, advisory, null interests: Bayer; Financial, personal interests, Guest speaker, null: Bayer; Financial, personal, advisory, null interests: Novartis / AAA; Financial, Personal, Advisory Board Interests, null: Beigene; Financial, personal, advisory, null interests: Remedy Bio; Financial, personal, advisory, null interests: Athenex; Financial, Personal, Advisory Board Interests, null: Telix; Financial, Personal, Advisory Board Interests, null: Clovis Oncology; Financial, personal, equity / equity interests, null: Curve Life; Financial and Institutional Interests, Research Grant, null: Clovis Oncology; Non-financial interests,, Advisory role, Unpaid advice: NHS England; Non-financial interests,, Advisory role, null: NICE NHS England.
Z. Malik: Financial, Personal, Advisory Board, Advisory Board for the new hormone therapy for breast cancer: sanofi; Other,, Other, support to attend meetings or advisory boards in the past: Astellas, Jaansen, Bayer.
C. Parker: Financial interests, personnel, advisory board, education steering committee: Bayer; Financial, personal interests, guest speaker, speaker at educational events on prostate cancer: Janssen; Financial, Personal, Advisory Board, Apalutamide Advisory Board: Janssen; Financial, personal, advisory board, advisory board interests: Clarity Pharmaceuticals; Financial interests, Staff, Advisory Board, Advisory Board on relugolix: Myovant; Financial, personal interests, advisory board, advisory board: ITM Oncologics.
Mr. R. Sydes: Financial, personal, guest speaker, lecturer fees in clinical trial statistics training sessions for clinicians (no discussion of specific drugs): Janssen; Financial, personal, guest speaker, lecturer fees at a training session on clinical trial statistics for clinicians (no discussion of specific drugs): Eli Lilly; Financial, institutional, research grant, educational grant and drug interest for the STAMPEDE trial: Astellas; Financial, institutional, research grant, educational grant, and biomarker costs for the STAMPEDE trial: Clovis Oncology; Financial, institutional, research grant, educational grant and drug interest for the STAMPEDE trial: Janssen; Financial, institutional, research grant, educational grant and drug interest for the STAMPEDE trial: Novartis; Financial, institutional, research grant, educational grant, and drug interest for the STAMPEDE trial: Pfizer; Financial, institutional, research grant, scholarship and drug interests for the STAMPEDE: Sanofi trial.
MK Parmar: Financial and Institutional Interests, Research Stock Exchange: AstraZeneca, Astellas, Janssen, Clovis.
ND James: Financial interests, Staff, Advisory Board, Advice around PARP inhibitors: AstraZeneca; Financial, personal, advisory board, prostate cancer therapy interests: Janssen; Financial, institutional interests, expert testimony, assistance with submissions regarding the licensing of abiraterone: Janssen; Financial Interests, Personnel, Advisory Board, Docetaxel: Sanofi; Financial and institutional interests, expert testimonials, supply of STAMPEDE test data to facilitate international license extensions for docetaxel: Sanofi; Financial Interests, Staff, Advisory Board, Prostate Cancer Therapies: Clovis; Financial, personal interests, advisory board, prostate cancer therapies: Novartis; Financial, personal interests, advisory board, bladder cancer treatment: Merck; Financial, institutional interests, guest speaker, funding of the STAMPEDE trial: Janssen; Financial, institutional interests, guest speaker, funding of the STAMPEDE trial: Astellas; Financial, institutional interests, guest speaker, funding of the RADIO bladder cancer trial: AstraZeneca.
All other authors have declared no conflicts of interest.


Source link

Comments are closed.